(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 134.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 103.75%.
Benitec Biopharma's earnings in 2026 is -$41,823,000.On average, 8 Wall Street analysts forecast BNTC's earnings for 2026 to be -$35,287,826, with the lowest BNTC earnings forecast at -$39,821,978, and the highest BNTC earnings forecast at -$32,710,910. On average, 7 Wall Street analysts forecast BNTC's earnings for 2027 to be -$39,981,130, with the lowest BNTC earnings forecast at -$40,817,527, and the highest BNTC earnings forecast at -$36,977,551.
In 2028, BNTC is forecast to generate -$31,546,050 in earnings, with the lowest earnings forecast at -$42,808,626 and the highest earnings forecast at -$12,088,815.